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Alpha-fetoprotein-producing carcinoma (AFPC)/hepatoid adenocarcinoma (HAC) and neuroendocrine carcinoma (NEC) are
uncommoninthestomach.Compositetumorsconsistingofthesecarcinomasandtheirhistologicphenotypesarenotwellknown.
Between 2002 and 2007, to estimate the prevalence of composite tumors consisting of tubular adenocarcinoma, AFPC/HAC and
NEC,wereviewedspecimensobtainedfrom294consecutivepatientstreatedsurgicallyforgastriccancer.Weexaminedhistological
phenotypeoftumorsofAFPCorNECcontainingthecompositetumorbyevaluatingimmunohistochemicalexpressionsofMUC2,
MUC5AC,MUC6,CDX2,andSOX2.Immunohistochemically,AFPC/HACdominantlyshowedtheintestinalormixedphenotype,
and NEC frequently showed the gastric phenotype. In the composite tumor, the tubular and hepatoid components showed the
gastric phenotype, and the neuroendocrine component showed the mixed type. The unique composite tumor predominantly
showed the gastric phenotype, and the hepatoid and neuroendocrine components were considered to be diﬀerentiated from the
tubular component.
1.Introduction
Alpha-fetoprotein (AFP) is a fetal protein produced by yolk
sac cells, fetal hepatic cells, and some fetal gastrointestinal
cells [1]. AFP-producing carcinoma (AFPC) is rare in the
stomach [2], although gastric adenocarcinoma is one of the
mostcommonmanifestationsofAFPC[3].Ishikuraetal.[4]
reported that hepatoid adenocarcinoma (HAC) is character-
ized by both hepatoid diﬀerentiation and AFP production,
while the histological features of hepatoid diﬀerentiation in
gastric AFPC have been determined. Gastric AFPC or HAC
frequently displays aggressive behavior [2, 5]; however, these
tumors exhibit many unresolved clinical and histopatholog-
ical features. On the other hand, neuroendocrine carcinoma
(NEC), including smallcellcarcinoma, is rarein the stomach
[6], and its clinicopathological features and clinical outcome
have been characterized recently [7, 8]. Both AFPC and NEC
were classiﬁed as special types of gastric carcinomas by the
Japanese Classiﬁcation of Gastric Carcinoma [9]. Composite
gastric tumors, consisting of special types of carcinoma,
have been insuﬃciently investigated. A composite gastric
tumor usually consists of both a common and a special
type of carcinoma, that is, well- or moderately diﬀerentiated
adenocarcinoma and HAC [4].
Gastric adenocarcinomas have been histopathologically
classiﬁed into four categories based on their cellular phe-
notype [10]. Several cellular markers, including MUC2,
MUC5AC, and MUC6, have been used to histochemically
investigate these phenotypes. It has been identiﬁed that
intestinal goblet cells, gastric foveolar epithelial cells, and
pyloric gland cells cause the expression of MUC2 [11],
MU5AC [12], and MUC6 [13], respectively. Measurement of
CDX2andSOX2expressiontoinvestigatecellularphenotype
has been adopted, recently. CDX2, homeobox gene has been2 Pathology Research International
known to play a role in the development of small and large
intestines [14], while transcription factor SOX2 is expressed
in normal stomach but not in the colon [15].
We examined the histological phenotypes of a composite
gastric tumor consisting of AFPC/HAC, NEC, and tubular
adenocarcinoma and investigated the cellular phenotypes
of AFPC and NEC by evaluating the immunohistochemical
expressions of MUC2, MUC5AC, MUC6, CDX2, and SOX2.
2.MaterialandMethods
2.1. Patients and Materials. To estimate the prevalence of
composite gastric tumors consisting of tubular adenocar-
cinoma, AFPC/HAC, and NEC, we reviewed gastrectomy
specimens obtained from 294 consecutive patients treated
surgically for gastric cancer during a 5-year period (2002–
2007) at Shinshu University Hospital. In addition to these
c o n s e c u t i v ec a s es e r i e s ,o n ec a s eo fc o m p o s i t eg a s t r i ct u m o r
of tubular adenocarcinoma, AFPC/HAC, and NEC was
included. These specimens were examined after obtaining
informed consent.
Three-micrometer-thick serial paraﬃns e c t i o n sw e r e
obtained from representative formalin-ﬁxed, paraﬃn-
embedded blocks and stained with hematoxylin and eosin
(HE) for histological examination or subsequent immun-
ohistochemical staining to investigate their cellular pheno-
type.
2.2. Histopathological Diagnosis. Gastric AFPC was histo-
pathologically diagnosed by a positive reaction of carcinoma
cells in AFP immunostaining with or without hepatoid
diﬀerentiation. NEC was suggested by the detection of
undiﬀerentiated carcinoma, including small cell carcinoma,
byHE-staining, anddiagnosed byapositive reactionofmore
than one-third of carcinoma cells for immunostaining with
several neuroendocrine markers, including neural cell adhe-
sion molecule (NCAM, CD56), chromogranin A (CGA),
synaptophysin (SP), and neuron-speciﬁc enolase (NSE).
Neuroendocrine markers were applied to tumors suspected
of neuroendocrine phenotype based on examination of HE
sections. According to the WHO 2010 classiﬁcation of neu-
roendocrine neoplasms [16], NEC is diagnosed by immun-
ostaining with Ki-67. Small cell carcinoma is deﬁned as
a tumor whose cells have scant cytoplasm, ﬁnely granular
nuclear chromatin, measure less than the diameter of three
small resting lymphocytes, and have faint nucleoli. Large cell
carcinoma is deﬁned as a tumor whose cells are large, with
moderate to abundant cytoplasm and round to oval nuclei
with frequent prominent nucleoli. All AFP and NEC cases
were examined in three to six blocks. The clinicopathological
features of gastric carcinomas are described in accordance
with the WHO 2010 Classiﬁcation of Tumours of the
Stomach [16].
2.3. Immunohistochemistry and Classiﬁcation of Cellular
Phenotypes. The expression of MUC2, MUC5AC, MUC6,
CDX2, and SOX2 was immunohistochemically investigated
to conﬁrm the presence cellular phenotypes of gastric
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Figure 1: Macroscopic ﬁnding of the resected stomach in Case
1. A type 3 tumor, 75 × 110mm in diameter, is located in the
u p p e rs t o m a c h .G r o s sp h o t o g r a p ho fc u ts e c t i o n si ss h o w n .B l u e
lines show a presence of NEC component, while red lines show
a presence of the tubular and hepatoid components based on the
histopathological ﬁndings.
AFPC or NEC. Microwave treatment was performed in
1mM EDTA/10mM Tris buﬀer (pH 8.0) for 25min. The
presence of more than one third of carcinoma cells in
immunostained samples was deﬁned as a positive reaction.
The commercially available antibodies for this immunos-
taining are shown in Table 2. Carcinomas were classiﬁed
into four categories based on their cellular phenotype in
accordance with immunohistochemical ﬁndings; intestinal,
mixed, gastric, or null (unclassiﬁed) phenotype [10]. This
phenotypicclassiﬁcation,amodiﬁedversionofthedeﬁnition
described by Kumashiro et al. [17], is summarized in Table 1.
3. Results
A composite gastric tumor consisting of AFPC/HAC, NEC,
and tubular adenocarcinoma was observed in only one
case (Case 1). In the resected specimen from this case, we
observed an ulcerated tumor (75 × 110mm) with no well-
deﬁned borders inﬁltrating into the surrounding tumor wall
(Figure 1(a)) .T h eN E Ca n dA F P Cc o m p o n e n t sw e r el o c a t e d
on the blue and red line, respectively, in cut sections of
theresectedspecimen(Figure 1(b)).Histopathologically,this
gastric carcinoma comprised of three types of components
(Figure 2(a)). Moderately diﬀerentiated tubular adenocar-
cinoma was identiﬁed (tubular component; Figure 2(b)),Pathology Research International 3
Table 1: Phenotypic classiﬁcation. Gastric carcinomas were classiﬁed four categories as follows; intestinal, mixed, gastric, and null
(unclassiﬁed) phenotypes. These categories were decided by immunohistochemical ﬁnding of MUC2, MUC5AC, and MUC6, and CDX2
and SOX2.
MUC5AC(−), and MUC6(−), and SOX2(−) MUC5AC(+), or MUC6(+), or SOX2(+)
MUC2(+) or CDX2(+) Intestinal type Mixed type
MUC2(−) and CDX2(−) Null type Gastric type
Table 2: Antibodies used for immunohistochemistry.
Antigen Clone Source Dilution Preparation
Neural cell adhesion molecule 123C3 (mm) Dako ×50 Microwave
Chromogranin A A0430 (rp) Dako ×200 —
Synaptophysin A0010 (rp) Dako ×100 Microwave
Neuron-speciﬁc enolase BBS/NC/VI-H14 (mm) Dako ×1( k i t ) M i c r o w a v e
Alfa-Fetoprotein A0008 (rp) Dako ×300 Microwave
Ki-67 MIB-1 (mp) Dako ×100 Microwave
MUC2 CCP58 (rp) Novocastra ×200 Microwave
MUC5AC 45M1 (rp) Novocastra ×300 Microwave
MUC6 CLH5 (rp) Novocastra ×200 Microwave
CDX2 CDX2-88 (mm) BioGene ×300 Microwave
SOX2 GT15098 (rp) Neuromi CS ×1000 Microwave
mm, mouse monoclonal antibody; rp, rabbit polyclonal antibody.
while other type of carcinoma cells, with large eosinophilic
and clear cytoplasm, had inﬁltrated with a trabecular or
sheet-like pattern that displayed the morphological features
of HAC (hepatoid component; Figure 2(c)). Furthermore,
undiﬀerentiated carcinoma cells had inﬁltrated the proximal
part of the tumor. This component had polygonal carcinoma
cells with prominent nucleoli in the nuclei, suggestive of
large cell NEC (neuroendocrine component; Figure 2(d)).
In this case, the NEC-cell component comprised of about
30% of the carcinoma, so this tumor was diagnosed not
as neuroendocrine diﬀerentiation but as a gastric-mixed
adenoneuroendocrine carcinoma (MANEC).
Clinicopathological features of patients with gastric
AFPC/HAC or NEC, including the composite gastric tumor
in Case 1, are shown in Table 3. Excluding Case 1,
AFPC/HAC was observed in four cases (1.4%), while NEC
was observed in six cases (2.0%). Among the six NEC cases,
the large and small cell types of EC were observed in four
and two cases, respectively. Among the four AFPC cases,
HAC was observed in one case. There was no case of a
composite gastric tumor consisting of AFPC/HAC and NEC,
excluding Case 1. Synchronous expression of both AFP and
neuroendocrine markers was not observed in any tumors;
moreover, the cooccurrence of gastric AFPC and NEC was
not observed in any tumors.
Immunohistochemical ﬁndings for diagnosis of compos-
itegastrictumor,AFPC/HACandNEC,areshowninTable 4.
All six NEC cases manifested a positive reaction for one
or more neuroendocrine markers, while no reaction was
evidenced for AFP. SP was expressed in all NEC cases, while
NCAM, CGA, and NSE were expressed in three NEC cases.
These neuroendocrine markers were completely expressed
in only one NEC case. None of the four AFPC/HAC
cases evidenced a reaction with neuroendocrine markers. In
Case 1, the tubular and hepatoid components evidenced a
positivereactionforAFP(Figure 3(a)),whilenoreactionwas
observed for neuroendocrine markers. The neuroendocrine
component of composite gastric tumor demonstrated pos-
itive reactions for CGA (Figure 3(b)) and SP, while no
reaction was observed for AFP.
Immunohistochemical ﬁndings for the cellular pheno-
types of composite gastric tumor, AFPC/HAC, and NEC
are shown in Table 4. MUC2 was expressed in one AFPC
case, while MUC5AC and MUC6 were expressed in the
other three cases. CDX2 was expressed in all AFPC/HAC
cases (Figure 3(c)), while SOX2 was expressed in one AFPC
case. MUC2 was expressed in one NEC case, MUC5AC was
expressed in the other NEC case, and MUC6 in four NEC
cases.CDX2wasnotexpressedinanyoftheNECcases,while
SOX2 was expressed in ﬁve NEC cases (Figure 3(d)). In NEC
cases, MUC6 was expressed in almost the same site when
comparedtoneuroendocrinemarkers.MUC2andMUC5AC
were expressed in the part of the positive site associated
with the neuroendocrine markers, but in diﬀerent areas to
each other. In Case 1, the tubular component evidenced
no reaction for MUC2, MUC5AC, or MUC6, but expressed
SOX2 (Figure 3(e)), and the hepatoid component expressed
MUC6 and SOX2. The neuroendocrine component did not
express MUC2, but expressed MUC5AC, MUC6, SOX2,
and CDX2 (Figure 3(f)). In all NEC cases, more than 20%
carcinoma cells are positive for Ki-67 (Figure 3(g)).
Consequently, with reference to the cellular phenotypes
in EC, gastric, mixed, and null phenotypes were observed
in four, one, and one case, respectively. In AFPC/HAC, the
intestinal and mixed phenotypes were observed in cases
one and three, respectively. In the composite gastric tumor,4 Pathology Research International
(a) (b)
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Figure 2: Histopathological ﬁndings of Case 1. Three types of carcinoma, including tubular adenocarcinoma, hepatoid adenocarcinoma,
and neuroendocrine carcinoma, are shown. The left side of the photograph shows the tubular and hepatoid components, while the right
side shows the neuroendocrine component. The tubular component is shown. The hepatoid component is shown. The neuroendocrine
component is shown.
Table 3: Clinicopathologic features of AFP-producing carcinoma and neuroendocrine carcinoma of the stomach.
Case Diagnosis Age Sex Site Size (mm) Histology T N M Outcome (months)
1 MANEC 83 M U 75 × 110 Tub 2 > hepatoid > large cell 4 2 1 DOD (6)
2 LCNEC 81 M M 25 × 20 Large cell 2 0 0 DOD (12)
3 LCNEC 74 M U 50 × 50 Large cell 2 3 0 DOD (13)
4 LCNEC 77 M U 90 × 80 Large cell 3 1 0 DOD (8)
5 LCNEC 62 M L 45 × 30 Large cell 2 1 0 alive (30)
6S C N E C 5 4 F U 9 × 8 Small cell 1 0 0 alive (66)
7 SCNEC 63 M U 65 × 60 Small cell 3 2 1 alive (24)
8A F P C 6 9 M U 4 0 × 32 Pap > tub 1 1 0 0 alive (30)
9A F P C 6 9 M U 6 0 × 50 Por > hepatoid 3 1 0 alive (42)
10 AFPC 70 M L 19 × 17 Tub 1 > tub 2 1 0 0 alive (66)
11 AFPC 51 M M 35 × 14 Tub 2 > tub 1 1 0 1 alive (24)
MANEC, mixed-adenoneuroendocrine carcinoma;
LCNEC, large-cell neuroendocrine carcinoma;
SCNEC, small-cell neuroendocrine carcinoma;
AFPC, alfa fetoprotein-producing carcinoma;
S i t e ;U ,u p p e r - t h i r d ;M ,m i d d l e - t h i r d ;L ,l o w e r - t h i r do ft h es t o m a c h .
Tub 1, well-diﬀerentiated tubular adenocarcinoma;
Tub 2, moderately diﬀerentiated tubular adenocarcinoma;
Pap, papillary adenocarcinoma;
Por, poorly diﬀerentiated adenocarcinoma;
DOD, died of disease.Pathology Research International 5
Table 4: Immunohistochemical ﬁndings of AFP-producing carcinoma and neuroendocrine carcinoma of the stomach.
Case Histology NCAM CGA SP NSE AFP MUC2 MUC5AC MUC6 CDX2 SOX2 Ki67 labeling index (%) Phenotype
Tubular −− − − + −−− − + 16 Gastric
1H e p a t o i d−− − − + −−+ − + 12 Gastric
LCNEC − ++−− − ++ + + 4 2 M i x e d
2L C N E C + + + −− − − + − + 24 Gastric
3L C N E C + + + + −− − + − + 32 Gastric
4L C N E C + − + −− +++ − +2 2M i x e d
5L C N E C−− + − − −−− − + 23 Gastric
6S C N E C−− ++ − −−− − − 32 Null
7S C N E C− +++−− − + − + 25 Gastric
8A F P C−− − − ++ −− + − 35 Intestinal
9A F P C−− − − + − ++ + − 18 Mixed
10 AFPC −− − − + − ++ + + 8 M i x e d
11 AFPC −− − − + − ++ + − 12 Mixed
LCNEC, large-cell neuroendocrine carcinoma;
SCNEC, small-cell neuroendocrine carcinoma;
AFPC, alfa fetoprotein-producing carcinoma;
NCAM, neural-cell adhesion molecule;
CGA, chromogranin A;
SP, synaptophysin;
NSE, neuron-speciﬁc enolase;
AFP, alfa fetoprotein.
the tubular and hepatoid components evidenced the gastric
phenotype, while the neuroendocrine component showed
the mixed phenotype.
4. Discussion
The composition of gastric AFPC/HAC and NEC is not yet
understood clinicopathologically. Only a few cases [18–20]
of gastric carcinoma consisting of AFPC/HAC and NEC have
been reported. Okamaoto et al. [18]r e p o r t e dac o m p o s i t e
gastric tumor consisting of AFPC and NEC, similar to the
present case. Rassidakis et al. [19]r e p o rt e dg a s t r i cH A Cwi t h
extensive neuroendocrine diﬀerentiation, and Ueda et al.
[20] reported a composite tumor consisting of poorly diﬀer-
entiated adenocarcinoma and NEC with synchronous AFP
expression. In the present study, no case of composite gastric
tumor consisting of AFPC/HAC and NEC was observed,
excluding Case 1. Furthermore, no case of gastric carcinoma
with synchronous expression of AFP and neuroendocrine
markers was observed. It was considered that this composi-
tion may be sporadic, and its occurrence may be very rare.
Gastric HAC frequently contains well- or moderately
diﬀerentiated adenocarcinoma including tubular adenocar-
cinoma [4, 21, 22]. Kishimoto et al. [23] suggested that HAC
developed from tubular adenocarcinoma, and Akiyama et al.
[21] reported that gastric HAC and adenocarcinomatous
components are of monoclonal origin. In the present
study, although HAC concomitant with adenocarcinoma
was observed in only one case, AFP was expressed in
well- or moderately diﬀerentiated adenocarcinomas. On the
other hand, mixed glandular exocrine tumors or composite
neuroendocrine exocrine tumors have been identiﬁed in the
stomach [24, 25], and NEC has frequently been associated
with an adenocarcinoma component in the stomach [24–
26]. These tumors have been deﬁned as adenocarcinoma and
NECincombinationinthesametumor.NECpredominantly
arises from endocrine precursor cell clones occurring in pre-
ceding adenocarcinoma components [26]. In other tumors,
such as pancreatic carcinomas [27] ,H A Cw a sf o u n dt ob e
associated with another cellular component, either NEC or
ductal carcinoma. Furthermore, several cases of hepatocellu-
larcarcinomawithneuroendocrinediﬀerentiationhavebeen
reported[28].Inthepresentstudy,sixgastricNECcaseswere
of the histologically pure type with no glandular component.
Although, as mentioned above, cases such as the composite
case presented are rare, gastric adenocarcinoma may also
have the potential to diﬀerentiate into other miscellaneous
types of carcinoma including either AFPC or NEC, such as
in this case.
Based on immunohistochemistry results for cellular
phenotype,Kumashiroetal.[17]recentlyreportedthatHAC
and adenocarcinomatous components mainly evidenced the
intestinal phenotype, and that the gastric phenotype was
not observed in HAC. In the present study, AFPC/HAC
expressed both intestinal and mixed phenotypes. On the
other hand, the cellular phenotype has not yet been analyzed
suﬃciently in gastric NEC. Iwafuchi et al. [29]r e p o r t e d
that, in Japanese subjects, gastric NEC frequently showed
the intestinal phenotype in immunohistochemical analyses
for CD10, MUC2, MUC5AC, and MUC6, with the com-
plete intestinal phenotype constituting 45.5% of cases and
incomplete intestinal phenotype consisting of 6.1% of the
cases in gastric NEC. In the present study, four of the six
EC cases evidenced the gastric phenotype immunohisto-
chemically. In the composite tumor, both the hepatoid and
the tubular components demonstrated the gastric phenotype6 Pathology Research International
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Figure 3: Immunohistochemistry for AFP-producing adenocarcinoma and neuroendocrine carcinoma. (a) AFP immunostaining in Case
1 (the tubular component of the composite tumor). A positive reaction for AFP is observed in the cytoplasm of the carcinoma cells. The
upper side of the photograph shows the tubular and hepatoid components with a positive reaction for AFP, while the lower side shows
the neuroendocrine component with a negative reaction for AFP. (b) Chromogranin A immunostaining in Case 1 (NEC component of
the composite tumor). A positive reaction for synaptophysin is observed in the cytoplasm of the carcinoma cells. The upper side of the
photograph shows the tubular and hepatoid components with a negative reaction for chromogranin A, while the lower side shows the
neuroendocrine component with a positive reaction for chromogranin A. (c) CDX2 immunostaining in Case 8 (usual case of AFPC). A
positive reaction for CDX2 is observed in the nuclei of tubular adenocarcinoma cells. (d) SOX2 immunostaining in Case 2 (usual case of
NEC). A positive reaction for SOX2 is observed in the nuclei of neuroendocrine carcinoma cells. (e) SOX2 immunostaining in Case 1 (the
tubular and hepatoid components). A positive reaction for SOX2 is observed in the nuclei of the carcinoma cells. (f) CDX2 immunostaining
in Case 1 (NEC component). A positive reaction for CDX2 is observed in the nuclei of the carcinoma cells. (g) Ki-67 immunostaining in
Case 1 (NEC component). More than 20% carcinoma cells are positive for Ki-67.
immunohistochemically. The neuroendocrine component
showed the presence of the mixed phenotype immunohis-
tochemically, but this ﬁnding was considered as a gastric
dominant type because MUC5AC, MUC6, and SOX2 were
expressed in the neuroendocrine component. The ﬁnding
that NEC evidenced the gastric dominant phenotype could
beusefulasareference.Theseﬁndingsforcellularphenotype
suggest that the hepatoid and neuroendocrine components
may diﬀer from the tubular component.
SOX2 has been shown to be downregulated in intestinal
metaplasia in the stomach [30], and its expression was
demonstrated in gastric adenocarcinoma with both gastric
and mixed phenotype [31]. CDX2 has been shown to be
expressed in intestinal development [14]a n dw a sd e m o n -
strated in intestinal metaplasia and adenocarcinoma with
the intestinal phenotype of the stomach [32, 33]. In the
present study, gastric NEC frequently expressed SOX2 but
not CDX2, while gastric AFPC/HAC frequently expressedPathology Research International 7
CDX2 but not SOX2. These NEC cases showed the presence
of the gastric phenotype, but AFPC/HAC may be considered
as being strongly associated with the intestinal phenotype. In
thecompositetumor,thethreecomponentsexpressedSOX2,
but CDX2 was expressed in the neuroendocrine component.
Therefore, this composite gastric tumor was considered to be
uniqueanddiﬀerentfromtypicalgastricNECorAFPC/HAC
cases.
In conclusion, this unique composite gastric tumor
predominantly evidenced the gastric phenotype, and the
hepatoid and neuroendocrine components were considered
to be diﬀerentiated from the tubular component. Generally,
gastric AFPC/HAC predominantly evidenced the intestinal
phenotype or mixed type, and NEC frequently showed the
gastric phenotype.
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